Brokerage Consensus Stocks: Jefferies, Nuvama and JM Financial back Polycab, Paytm, Coforge and more with upside potential up to 88%.
BSE emerged as FY26’s surprise winner with profit nearly doubling on booming derivatives and trading activity, while NSE’s earnings were…
Britannia drops while Thermax, Sonata, Pidilite and Dabur rally after Q4FY26 earnings and major block deals.
Buybacks are rapidly regaining favour among cash-rich Indian companies after Budget 2026 sharply improved tax efficiency for minority shareholders. According…
Aurobindo Pharma announces Rs 800 crore buyback at 6% premium, opening April 23. Check eligibility and key dates!
Railway stocks are suddenly back in focus, Wipro lands a billion-dollar deal, but FMCG weakness is dragging the market here’s…
Markets stayed muted, but stock-specific action dominated as Trent, Senco Gold and Ola Electric surged while auto stocks dragged.
Aurobindo Pharma’s Rs 800 crore buyback: Key date set—what investors should check.
Sun Pharma may be the most exposed to US tariffs but a global buffer could quietly limit the real damage.
A sharp sell-off gripped markets as pharma stocks plunged on US tariff fears and rising crude prices dragged key sectors,…
JM Financial has flagged three high-conviction stock picks across auto, aerospace, and pharma sectors, with upside potential reaching up to…
Let’s take a look at a few stocks you can keep on your watchlist as the war rages in West…
Stocks to watch today, February 20: Track market trends with updates on REC-PFC merger, Swiggy’s Snacc exit, Nykaa’s new partnership,…
Eicher jumps 6%, M&M profit surges 47% while Aurobindo slides 8% as Q3 earnings drive sharp stock moves.
US slashes tariffs on Indian goods to 18%, boosting exports and investments. Axis Direct identifies top 25 Indian stocks in…
Post-Budget trends signal near-term dips across 8 key Nifty sectors; review support and resistance levels before making investment decisions.
Super investor and a Warren Buffett of India, Mukul Agarwal, has just added two new stocks to his portfolio sending…
Aurobindo Pharma’s wholly owned subsidiary Auro Pharma acquires Khandelwal Laboratories’ non-oncology prescription formulations business for Rs 325 crore in a…